Popular medications indicated for Type 2 diabetes or chronic weight management, including Ozempic, Mounjaro and Wegovy, are dancing through a flood of research for broader indications. 

CVS is planning to close dozens of pharmacies inside Target stores this year, The Wall Street Journal reported Jan. 11.

On Jan. 11, the FDA said it has not found a causal link between glucagon-like peptide-1 receptor agonists, such as Ozempic and Mounjaro, and suicidal thoughts.

Even after the FDA issued a warning in 2020 about the adverse effects linked to Singulair, a now generic asthma drug, and strengthened its warning in 2022, physicians continue to prescribe it to millions of patients.

Experts and industry analysts largely agree Eli Lilly's new direct-to-consumer platform will increase access to patients who may benefit from its new anti-obesity drug Zepbound, but questions are being raised surrounding appropriate care coordination and the business model behind the offering. 

A 6-year-old patient received three extra doses of two chemotherapies in late 2022, and the FDA sent Children's Hospital of Michigan a warning letter about the mistake. 

Eli Lilly's CEO said supply of Zepbound, the drugmaker's new weight loss drug, might not meet 2024 demand. 

Ozempic and other glucagon-like peptide-1 receptor agonists are not linked to a higher risk of pancreatic cancer compared to insulin, according to a recent study. 

Vertex Pharmaceuticals paused a Type 1 diabetes drug trial after two patients died. The drugmaker said the deaths are unrelated to the therapy and that it is waiting on independent review before restarting the study. 

New research points to a challenge patients may face once they stop taking a GLP-1 medication: The number of calories they consume may rise. 

The FDA is looking into 22 reports of patients contracting blood cancer after receiving CAR-T therapy treatment. The move comes after the agency reported initial investigation efforts into cases in November. 

Leiters Health has recalled 33 lots of IV bags filled with vancomycin, phenylephrine and fentanyl because the solutions might contain double the amount labeled. 

Merck is acquiring South San Francisco-based Harpoon Therapeutics, an oncology drugmaker, for approximately $680 million.

Lindsey Amerine, PharmD, was named chief pharmacy officer of Cleveland Clinic, effective Feb. 26. 

Johnson & Johnson plans to acquire Ambrx, a clinical-stage biotechnology company developing cancer treatments, for $1.9 billion. 

Eli Lilly's recent launch of a direct-to-consumer prescription drug website isn't expected to overthrow the pharmaceutical supply chain, but competitors are likely to take inspiration, CNBC reported Jan. 5. 

Sen. Bernie Sanders, I-Vt., and three other legislators on the Health, Education, Labor and Pensions Committee launched an investigation into inhalers, calling the prices "outrageous."

Hospital pharmacies are criticizing Florida's plan to import drugs from Canada, arguing the idea undermines the pharmacist-patient relationship and fails to be a "real solution."

Hospital pharmacy leaders should be vigilant about eradicating the syringe drawback method —  and taking pictures during sterile compounding isn't enough, according to Rita Jew, PharmD, president of the Institute for Safe Medication Practices. 

Ozempic is facing increased competition from compounded versions and rival drugmakers, while potential side effects, including suicidal thoughts and hair loss, have spurred investigations into it and similar drugs.